FDA Grants Partner Therapeutics Seventh CNPV Approval for Zenocutuzumab-zbco in Rare Bile Duct Cancer

Compressed review timelines under the Commissioner's National Priority Voucher (CNPV) pilot program are becoming a structural reality: the FDA's seventh approval under the program, issued May 8, 2026, covers Bizengri (zenocutuzumab-zbco) for NRG1 fusion-positive cholangiocarcinoma, and signals that accelerated rare disease pathways are moving from pilot novelty to operational norm. Regulatory affairs leads at contract manufacturers and biologics sponsors should be calibrating submission readiness accordingly.

Partner Therapeutics, Inc. received the approval for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion following disease progression on prior systemic therapy. Bizengri is the first drug approved in this specific indication. Efficacy data derive from a single-arm trial of 19 patients, with an overall response rate of 36.8% and duration of response ranging from 2.8 to 12.9 months, a dataset that reflects the evidentiary standards applicable to ultra-rare oncology indications under accelerated approval.

The biologic carries Breakthrough Therapy and Orphan Drug designations. Its 2024 accelerated approval for NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma established the post-marketing commitment framework that now extends to this cholangiocarcinoma indication. QA and regulatory teams managing biologics with accelerated approval status should confirm that confirmatory trial protocols and CAPA structures tied to post-marketing requirements remain current and inspection-ready.

From a pharmacovigilance and labeling standpoint, the safety profile warrants attention for infusion suite operations and risk management planning. Serious adverse events include infusion-related reactions, interstitial lung disease/pneumonitis, and left ventricular dysfunction. Common adverse events span diarrhea, musculoskeletal pain, fatigue, nausea, dyspnea, rash, and edema, a profile that informs both label negotiations and post-approval safety reporting obligations under 21 CFR Part 314 and applicable biologics regulations.

The FDA will host a public meeting on June 4, 2026, to solicit stakeholder input on CNPV eligibility criteria, the voucher selection process, sponsor responsibilities, pre-submission requirements, FDA review procedures, and the role of the CNPV review council. Written comments are accepted through June 29, 2026, a window that gives regulatory affairs leads a defined interval to formally shape program implementation before it scales further.

The June 4 meeting outcome and the volume of written comments received through June 29 will likely determine how the CNPV program's eligibility and review procedures are codified for future rare disease submissions.

Source: FDA press announcement via FDA.gov, May 8, 2026.